Daiichi Sankyo is bringing a seventh antibody-drug conjugate, or ADC, into its pipeline through a licensing agreement with German biotech Glycotope. Specific financials weren’t disclosed, …
Allergan on Thursday touted data from two late-stage trials that showed a drug it in-licensed from a Swiss biotech proved non-inferior to Lucentis in the …
China has more than 114 million people living with diabetes, the largest number of any country in the world Global drug giant, Merck signed an …
Doctors and teaching hospitals received $8.4 billion from drug and device companies in 2017, according to the latest Centers for Medicare and Medicaid Services Open …
Oncology already sits as the top-selling therapeutic area on the orphan drug market, but a new report predicts it to account for even more — …
Amgen and Novartis on Thursday secured Food and Drug Administration approval for Aimovig, the first regulatory thumbs up for a new class of migraine treatments …
Brief: United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in …
AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHRII …
